Page 44 - Read Online

Briggs et al. J Cancer Metastasis Treat 2021;7:46 https://dx.doi.org/10.20517/2394-4722.2021.84 Page 13 of 13

47. Rini B, Huseni M, Atkins M, et al. Molecular correlates differentiate response to atezolizumab (atezo) + bevacizumab (bev) vs
sunitinib (sun): Results from a phase III study (IMmotion151) in untreated metastatic renal cell carcinoma (mRCC). Ann Oncol
2018;29:viii724-5. DOI
48. Beuselinck B, Verbiest A, Couchy G, et al. Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic
clear-cell renal cell carcinoma. Acta Oncol 2018;57:498-508. DOI PubMed
49. Shen M, Chen G, Xie Q, et al. Association between PD-L1 expression and the prognosis and clinicopathologic features of renal cell
carcinoma: a systematic review and meta-analysis. Urol Int 2020;104:533-41. DOI PubMed
50. Choueiri TK, Figueroa DJ, Fay AP, et al. Correlation of PD-L1 tumor expression and treatment outcomes in patients with renal cell
carcinoma receiving sunitinib or pazopanib: results from COMPARZ, a randomized controlled trial. Clin Cancer Res 2015;21:1071-7.
DOI PubMed
51. Thompson RH, Kuntz SM, Leibovich BC, et al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with
long-term follow-up. Cancer Res 2006;66:3381-5. DOI PubMed
52. Boland JM, Kwon ED, Harrington SM, et al. Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. Clin Lung
Cancer 2013;14:157-63. DOI PubMed
53. Bigelow E, Bever KM, Xu H, et al. Immunohistochemical staining of B7-H1 (PD-L1) on paraffin-embedded slides of pancreatic
adenocarcinoma tissue. J Vis Exp 2013:4059. DOI PubMed PMC
54. Lyford-Pike S, Peng S, Young GD, et al. Evidence for a role of the PD-1:PD-L1 pathway in immune resistance of HPV-associated
head and neck squamous cell carcinoma. Cancer Res 2013;73:1733-41. DOI PubMed PMC
55. Wintterle S, Schreiner B, Mitsdoerffer M, et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism
of immune paralysis. C. ancer Res 2003;63:7462-7. PubMed
56. Zhang Y, Huang S, Gong D, Qin Y, Shen Q. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating
CD8+ T lymphocytes in human non-small cell lung cancer. Cell Mol Immunol 2010;7:389-95. DOI PubMed PMC
57. Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S. Overexpression of B7-H1 (PD-L1) significantly associates with
tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol Immunother 2007;56:1173-82. DOI PubMed
58. Thompson RH, Gillett MD, Cheville JC, et al. Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness
and potential therapeutic target. Proc Natl Acad Sci U S A 2004;101:17174-9. DOI PubMed PMC
59. Motzer RJ, Escudier B, Oudard S, et al; RECORD-1 Study Group. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final
results and analysis of prognostic factors. Cancer 2010;116:4256-65. DOI PubMed
60. Motzer RJ, Rini BI, Mcdermott DF, et al. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell
carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol 2019;20:1370-
85. DOI PubMed PMC
61. Shao Y, Wu B, Jia W, Zhang Z, Chen Q, Wang D. Prognostic value of pretreatment neutrophil-to-lymphocyte ratio in renal cell
carcinoma: a systematic review and meta- analysis. BMC Urol 2020;20:90. DOI PubMed PMC
62. Yuk HD, Kang M, Hwang EC, et al; Korean Renal Cancer Study (KRoCS) Group. The platelet-to-lymphocyte ratio as a significant
prognostic factor to predict survival outcomes in patients with synchronous metastatic renal cell carcinoma. Investig Clin Urol
2020;61:475-81. DOI PubMed PMC
63. Singla N, Xie Z, Zhang Z, et al. Pancreatic tropism of metastatic renal cell carcinoma. JCI Insight 2020;5:134564. DOI PubMed
PMC
64. Motzer RJ, Escudier B, McDermott DF, et al; CheckMate 025 Investigators. Nivolumab versus everolimus in advanced renal-cell
carcinoma. N Engl J Med 2015;373:1803-13. DOI PubMed PMC
65. Choueiri TK, Motzer RJ, Rini BI, et al. Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib
versus sunitinib in patients with advanced renal cell carcinoma. Ann Oncol 2020;31:1030-9. DOI PubMed
66. Rini BI, Powles T, Atkins MB, et al. Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic
renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial. Lancet 2019;393:2404-15. DOI
PubMed
67. Motzer RJ, Tannir NM, McDermott DF, et al; CheckMate 214 Investigators. Nivolumab plus ipilimumab versus sunitinib in advanced
renal-cell carcinoma. N Engl J Med 2018;378:1277-90. DOI PubMed PMC
68. Rini BI, Motzer RJ, Powles T, et al. Atezolizumab plus bevacizumab versus sunitinib for patients with untreated metastatic renal cell
carcinoma and sarcomatoid features: a prespecified subgroup analysis of the IMmotion151 clinical trial. Eur Urol 2021;79:659-62.
DOI PubMed
69. Danaher P, Warren S, Lu R, et al. Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS):
results from The Cancer Genome Atlas (TCGA). J Immunother Cancer 2018;6:63. DOI PubMed PMC
70. Fong PC, Boss DS, Yap TA et al. Inhibition of poly(ADP-Ribose) polymerase in tumors from BRCA mutation carriers. Available
from: https://www.nejm.org/doi/pdf/10.1056/NEJMoa0900212?articleTools=true. [Last accessed on 1 Jul 2021].
71. Rini BI, Plimack ER, Stus V, et al; KEYNOTE-426 Investigators. Pembrolizumab plus axitinib versus sunitinib for advanced renal-
cell carcinoma. N Engl J Med 2019;380:1116-27. DOI PubMed
72. Plimack ER, Rini BI, Stus V, et al. Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma
(RCC): Updated analysis of KEYNOTE-426. JCO 2020;38:5001. DOI